Colleen Tracy James and Neil DuChez ask, is biosimilar litigation the new frontier as predicted or an area pursued less vigorously as under the Hatch-Waxman Act because of cost and manufacturing obstacles?
Colleen Tracy James and Neil DuChez
Advertisement
Colleen Tracy James is a partner and Neil DuChez an associate, both in the intellectual property group of Mayer Brown LLP.
Articles by Colleen Tracy James and Neil DuChez
Advertisement
Latest Updated Articles
Patent Strategy Implications in the Biosimilars SpacePublished: April 11th 2015 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
